Sucampo Pharmaceuticals, Inc. (SCMP) Earns Buy Rating from Analysts at B. Riley

Research analysts at B. Riley assumed coverage on shares of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) in a research report issued on Tuesday. The brokerage set a “buy” rating and a $14.00 price target on the biopharmaceutical company’s stock. B. Riley’s target price suggests a potential upside of 35.92% from the company’s current price.

A number of other brokerages also recently weighed in on SCMP. Maxim Group set a $23.00 price target on shares of Sucampo Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, August 2nd. TheStreet downgraded shares of Sucampo Pharmaceuticals from a “c+” rating to a “d” rating in a report on Wednesday, August 2nd. Leerink Swann initiated coverage on shares of Sucampo Pharmaceuticals in a report on Monday, August 21st. They issued an “outperform” rating and a $15.00 price target for the company. Roth Capital set a $30.00 price target on shares of Sucampo Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, August 3rd. Finally, Zacks Investment Research raised shares of Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating and set a $11.00 price target for the company in a report on Tuesday, October 17th. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Sucampo Pharmaceuticals has an average rating of “Buy” and a consensus price target of $16.22.

Shares of Sucampo Pharmaceuticals (NASDAQ:SCMP) opened at $10.30 on Tuesday. The company has a quick ratio of 4.46, a current ratio of 5.11 and a debt-to-equity ratio of 7.37. Sucampo Pharmaceuticals has a 1-year low of $9.30 and a 1-year high of $17.55. The firm has a market cap of $499.01, a price-to-earnings ratio of 7.33, a price-to-earnings-growth ratio of 3.21 and a beta of 1.38.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last issued its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported $0.27 earnings per share for the quarter, beating analysts’ consensus estimates of $0.25 by $0.02. Sucampo Pharmaceuticals had a negative net margin of 60.24% and a positive return on equity of 74.58%. The firm had revenue of $61.27 million during the quarter, compared to the consensus estimate of $58.05 million. During the same period in the prior year, the firm earned $0.30 EPS. The business’s revenue was up 5.9% on a year-over-year basis. equities research analysts predict that Sucampo Pharmaceuticals will post 1.11 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This report was published by Markets Daily and is the property of of Markets Daily. If you are accessing this report on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The original version of this report can be read at https://www.themarketsdaily.com/2017/11/14/sucampo-pharmaceuticals-inc-scmp-earns-buy-rating-from-analysts-at-b-riley.html.

In other news, insider Jason Patrick Meyenburg purchased 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 6th. The stock was purchased at an average cost of $12.13 per share, with a total value of $48,520.00. Following the acquisition, the insider now directly owns 30,228 shares of the company’s stock, valued at approximately $366,665.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Sachiko Kuno sold 1,000,000 shares of Sucampo Pharmaceuticals stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $12.00, for a total transaction of $12,000,000.00. The disclosure for this sale can be found here. 4.13% of the stock is currently owned by company insiders.

Hedge funds have recently made changes to their positions in the stock. AlphaMark Advisors LLC lifted its holdings in Sucampo Pharmaceuticals by 25.4% during the 2nd quarter. AlphaMark Advisors LLC now owns 98,400 shares of the biopharmaceutical company’s stock valued at $1,033,000 after purchasing an additional 19,900 shares during the last quarter. Swiss National Bank lifted its holdings in Sucampo Pharmaceuticals by 22.3% during the 2nd quarter. Swiss National Bank now owns 43,859 shares of the biopharmaceutical company’s stock valued at $461,000 after purchasing an additional 8,000 shares during the last quarter. Texas Permanent School Fund increased its position in Sucampo Pharmaceuticals by 2.2% in the 2nd quarter. Texas Permanent School Fund now owns 18,319 shares of the biopharmaceutical company’s stock valued at $192,000 after acquiring an additional 398 shares in the last quarter. Eqis Capital Management Inc. increased its position in Sucampo Pharmaceuticals by 28.5% in the 3rd quarter. Eqis Capital Management Inc. now owns 40,651 shares of the biopharmaceutical company’s stock valued at $480,000 after acquiring an additional 9,012 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in Sucampo Pharmaceuticals by 48.9% in the 1st quarter. Vanguard Group Inc. now owns 1,456,787 shares of the biopharmaceutical company’s stock valued at $16,024,000 after acquiring an additional 478,226 shares in the last quarter. 56.79% of the stock is owned by hedge funds and other institutional investors.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Analyst Recommendations for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply